Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Jiankang Yuan's COPD dual-target innovative drug makes important progress: Phase I safety is good, and the first patient has been enrolled in Phase II.

Published Time:

2024-11-15

Following the launch of a new generation of innovative glucocorticoid drugs and asthma innovations After the GSNOR inhibitor entered Phase II, Healthy Yuan's respiratory innovation drug field has again delivered good news. Recently, the company's MABA dual-target innovative drug for chronic obstructive pulmonary disease (COPD) showed good safety in Phase I experiments and has officially entered Phase II clinical trials and enrolled the first patient, marking another solid step towards commercialization.

 

 

New drug MABA dual-target synergistic effect, with both rapid and long-acting therapeutic advantages

 

Studies have shown that this drug showed good safety in Phase Ib clinical trials, and participants did not experience serious adverse reactions, laying a solid foundation for the ongoing Phase II study.

 

As a common chronic respiratory disease worldwide, COPD is most typically characterized by airway inflammation and airway hyperresponsiveness. Currently, the most common drugs on the market include LAMA and LABA. Among them, LAMA drugs focus on improving airflow limitation and reducing the risk of acute exacerbations; while LABA aims to enhance airway patency and relieve symptoms such as shortness of breath in patients. However, LABA and LAMA are both single-target mechanism drugs, and when dealing with complex chronic diseases such as COPD, they have obvious limitations in efficacy compared to dual-target drugs.

 

Healthy Yuan's launch of First-in-class inhaled drug MABA has a unique “dual-target” mechanism of action achieving an innovative design that simultaneously acts on two major targets on a single molecule, providing a new solution to the current COPD treatment challenges:

1) Synergistic dual-target, improved efficacy : The dual-target mechanism not only successfully avoids the limitations in efficacy and potential side effects that may be encountered with LAMA and LABA monotherapy, but also achieves dual improvement in COPD symptoms and pulmonary function through the synergistic effect of the “dual-target”, significantly improving treatment efficacy and patient adherence.

2) Balancing rapid and long-acting effects, highlighting therapeutic advantages : Data show that the drug has both rapid and long-acting therapeutic advantages, able to quickly respond to acute needs and achieve rapid relief, while also suitable for long-term maintenance therapy, and is expected to provide a strong supplement or even replacement for existing treatment regimens.

3) Safe design, worry-free treatment: The drug's unique quaternary ammonium salt structural design effectively prevents the drug from entering the central nervous system, thereby significantly reducing the possibility of side effects on the central nervous system and improving treatment safety, bringing a more efficient, convenient, and safe new treatment option for COPD patients.

 

This innovative mechanism drug can successfully enter Phase II clinical trials, which is undoubtedly good news for COPD patients.

 

Leading the respiratory formulation field, achieving breakthroughs with multiple innovative drugs

 

Since 2013, Healthy Yuan has focused on R&D, production, and sales in the respiratory field, becoming one of the earliest companies in China to deploy inhaled formulations. Relying on multiple innovative product lines and major technological breakthroughs, Healthy Yuan's market share in China has grown rapidly, and it has successfully entered the top ranks of the industry, breaking the market pattern that has long been dominated by overseas pharmaceutical companies.

 

Currently, the respiratory field has become one of Healthy Yuan's strengths and iconic sectors. The company has launched a number of classic products for respiratory inhalation and nebulization treatment, and has 10 varieties and 14 specifications of products on the market and more than 20 respiratory products under development. Notably, after in-depth adjustments to the company's R&D structure and system construction, Healthy Yuan has accelerated its focus on innovative drug R&D projects, and has currently launched 11 innovative drugs, with 5 having advanced to Phase II and beyond.

 

This breakthrough in the development of the MABA dual-target innovative drug is not only another important layout of Healthy Yuan's innovative drug pipeline in the respiratory field, but also a further highlight of the company's innovative R&D system capabilities. With the steady progress of subsequent clinical research and commercialization, Healthy Yuan is expected to bring more benefits to COPD patients worldwide and occupy a more important position in the COPD treatment field.